Navigation Links
Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Date:10/3/2008

CHICAGO, Oct. 3 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced that on October 1, 2008 the Nasdaq Listings Qualifications Department informed the Company that the market value of its listed securities was below $35 million for 10 consecutive days, which is the requirement for continued listing on the Nasdaq Capital Market according to Marketplace Rule 4310(c)(3)(B). Nasdaq also informed the Company that it is not in compliance with Marketplace Rule 4310(c)(3)(A) or 4310(c)(3)(C), which require minimum stockholders' equity of $2,500,000 or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

Advanced Life Sciences has been provided 30 calendar days, or until October 31, 2008, to regain compliance with the continued listing requirements of the Nasdaq Capital Market. If at anytime prior to October 31, 2008, the market value of listed securities of the Company's common stock is $35 million or more for a minimum of 10 consecutive business days, this could constitute meeting the criteria for continued listing on the Nasdaq Capital Market.

In the event that the Company does not regain compliance by October 31, 2008, Advanced Life Sciences will have the right to appeal a determination to delist its securities from the Nasdaq Capital Market. The Company's securities would remain listed on the Nasdaq Capital Market throughout the appeal process.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical com
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the ... received a Canadian Patent for Inhibition or Reversal ... includes claims using thymosin beta 4, various fragments ... these purposes.  The patent will expire in 2021. ... www.regenerx.com ) RegeneRx is focused ...
(Date:9/30/2014)... 30, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... Office (USPTO) issued U.S. Patent No. 8,816,083 to ... Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates ... Thereof." The patent, which extends through ...
(Date:9/30/2014)... The custom stainless steel fabrication company HOLLOWAY ... The Boston Area Chapter of ISPE (International Society for ... for Wed., Oct. 1 at Gillette Stadium Clubhouse in ... in ISPE Boston’s long history, with more than 375 ... , HOLLOWAY AMERICA President David Simpson is looking ...
(Date:9/30/2014)... 30, 2014 UFP Technologies, a ... packaging has recently introduced a custom insulated shipping ... . The new insulated shipper solves the issue ... process. UFP Technologies’ BioShell is a universal storage ... storage, handling and shipping. The insulated shipper keeps ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3
... Smilodon ranks alongside Tyrannosaurus rex as the ultimate killing ... was a fearsome predator of Ice-Age America,s lost giants. ... debated how this iconic predator used its ferocious fangs ... published today in the US Proceedings of the National ...
... 1 Boston Scientific,Corporation (NYSE: BSX ) will ... quarter ended September 30, 2007 on Friday,October 19, at ... by Jim Tobin, President and Chief Executive,Officer, Paul LaViolette, ... Chief Financial Officer. The live webcast and archived ...
... Space Center,has awarded a five-year, $120-million extension of ... Institute, also known,as NSBRI, of Houston. Under the ... continue biomedical research in support of a,long-term human ... the cooperative agreement began April 1, 1997, with,a ...
Cached Biology Technology:Scientists say sabercat bit like a pussycat 2Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results 2
(Date:9/30/2014)... in almost any aquatic environment on Earth, but when ... are pushed to the limit. The amount of time ... for how different species cope in the future, reveals ... Gothenburg, published in the scientific journal Proceedings of ... apace thanks to increasing levels of greenhouse gases in ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... Calif. Beyond the personal tragedy of chronic alcoholism ... know severe alcoholism stresses the heart and that mitochondria, ... But they don,t know the precise mechanism. Now ... Center of the New York State Department of Health ...
... 22, 2012 -- The first clinical trial of a ... by the Infectious Disease Research Institute (IDRI), a Seattle-based ... diseases of poverty. The Phase 1 trial is taking ... trial planned in India, an epicenter of the disease. ...
... an outbreak of airborne H5N1 influenza in humans needs to ... can safely continue H5N1 research and share the results among ... mBio , the online open-access journal of the American Society ... been at the center of heated discussions in science and ...
Cached Biology News:A change of heart 2First vaccine against fatal visceral leishmaniasis enters clinical trial 2First vaccine against fatal visceral leishmaniasis enters clinical trial 3Opinion: H5N1 flu is just as dangerous as feared, now requires action 2Opinion: H5N1 flu is just as dangerous as feared, now requires action 3
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Latanoprost EIA Antiserum EIAs neutrophils antisera enzyme immunoassays reagents...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: